Innovent Biologics reports interim results
Source: SeekingAlpha
2025-08-27 06:27:08 ET
More on Innovent Biologics
- Neutral On Innovent Biologics: Hard To Justify Its Premium
- How mazdutide compares against weight loss therapies from Novo Nordisk, Lilly
- Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide
- Historical earnings data for Innovent Biologics
- Financial information for Innovent Biologics
Read the full article on Seeking Alpha
For further details see:
Innovent Biologics reports interim results
Innovent Biologics Inc
NASDAQ: IVBXF
IVBXF Trading
-1.19% G/L:
$9.95 Last:
8,095 Volume:
$10 Open:
